Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "NSAIDs"

A Comprehensive Review of NSAID Cardiovascular Toxicity

A Comprehensive Review of NSAID Cardiovascular Toxicity

Deepan S. Dalal, MD, MPH, Maureen Dubreuil, MD, MS, & David T. Felson, MD, MPH  |  July 18, 2018

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

FDA to Review Abuse-Deterrent Oxycodone Capsule

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2018

FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Michele B. Kaufman, PharmD, BCGP  |  April 2, 2018

A recent study examined how often patients exceed the dosing limits of nonsteroidal anti-inflammatory drugs and identified the characteristics of the patients most likely to exceed recommended doses…

Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain

Lisa Rapaport  |  March 7, 2018

(Reuters Health)—Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests. And opioids are no better than these other drugs at reducing how much pain interferes with daily activities, such as walking, working, sleeping or enjoying…

Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib

Anne Harding  |  September 12, 2017

NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…

Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?

Marilynn Larkin  |  June 8, 2017

(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say. Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned…

NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin

Michele B. Kaufman, PharmD, BCGP  |  May 29, 2017

NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…

Spinal Manipulation Might Help Ease Acute Low Back Pain

Lisa Rapaport  |  April 11, 2017

(Reuters Health)—Spinal manipulation may work as well for easing lower back pain as anti-inflammatory medications, a research review concludes. Based on data from 15 previously conducted trials involving a total of 1,711 adults, the study team found that spinal manipulation achieved meaningful reductions in pain and improvements in function after six weeks of treatment. The…

Insights into Drug-Related Interactions in Older Adults

Michele B. Kaufman, PharmD, BCGP  |  February 9, 2017

A study showed that prior hospitalization and the use of multiple medications are risk factors for drug and drug–disease interactions…

Celecoxib & Cardiovascular Death: NSAID Safety Under Review

Michele B. Kaufman, PharmD, BCGP  |  December 7, 2016

A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences